Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development Arrangement - Purchase Price Allocation (Details) - USD ($) $ in Millions		Dec. 31, 2023	Dec. 14, 2023	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill	[1]	$ 67,783		$ 51,375	$ 49,208
Seagen [Member]
Business Acquisition [Line Items]
Working capital, excluding inventories	[2]		$ 736
Inventories	[3]		4,195
Property, plant and equipment			524
Identifiable intangible assets, excluding in-process research and development	[4]		7,970
In-process research and development			20,800
Other noncurrent assets			174
Net income tax accounts	[5]		(6,123)
Other noncurrent liabilities			(167)
Total identifiable net assets			28,108
Goodwill			16,126
Net assets acquired/total consideration transferred			$ 44,234

[1] Our goodwill balance continues to be assigned within the Biopharma reportable segment.

[2] Includes cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued compensation and other current liabilities.

[3] Comprised of $1.0 billion current inventories and $3.1 billion noncurrent inventories.

[4] Comprised mainly of $7.5 billion of finite-lived developed technology rights with an estimated weighted-average life of approximately 18 years.

[5] As of the acquisition date, included primarily in Noncurrent deferred tax liabilities.